Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/IIa Clinical Trial Assessing Safety, Pharmacokinetics, Behavioral and Brain Effects of DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression

Next Previous
Trial Profile

Phase I/IIa Clinical Trial Assessing Safety, Pharmacokinetics, Behavioral and Brain Effects of DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs N-N-dimethyltryptamine (Primary)
  • Indications Depression
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Biomind Labs

Most Recent Events

  • 03 May 2022 New trial record
  • 26 Apr 2022 According to Biomind Labs media release, the company has commenced dose administration of the first subject in this trial; The trial has commenced on time and as scheduled and is being administered by superior medical practices at Biomind's new clinical psychedelic research facility in the University Hospital Onofre Lopes. Led by Dr. Draulio Araujo,
  • 26 Apr 2022 According to Biomind Labs media release, first phase of the study includes up to thirty healthy patients and dosing is expected to be completed in approximately four months

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top